Navigation Links
FLIPR Calcium Assay Kit Datasheet

ENABLING HIGH-THROUGHPUT, LOW-COST ASSAYS



NO WASH STEPS

IMPROVED DATA

HIGHER THROUGHPUT

LOW COST


Every major pharmaceutical company uses the Molecular Devices FLIPR fluorometric imaging plate reader system in its drug discovery process. The FLIPR Calcium Assay Kit from Molecular Devices provides the easiest way to get the best performance from your FLIPR system.


OPTIMIZED NO-WASH ASSAY
The FLIPR Calcium Assay Kit was developed and optimized for the FLIPR system to provide a fast, simple and reliable fluorescence-based assay for detecting changes in intracellular calcium. With this kit, calcium assays on FLIPR become a Mix-and-Read procedure in which cells are incubated with the kit reagents for up to one hour and transferred directly to the FLIPR system for evaluation. There are no intermediate wash steps involved.


IMPROVED PHYSIOLOGICAL DATA
The major benefit of the optimized assay is apparent in the quality of the data. The signal obtained with the FLIPR Calcium Assay Kit tends to be higher than that observed in cells loaded with fluo-3 and, at a minimum, comparable to that seen with fluo-4 dye-loaded cells. Furthermore, tighter CVs across 96- and 384-well plates are observed, leading to better results. Figures 1 and 2 show typical data using the FLIPR Calcium Assay Kit.


HIGHER THROUGHPUT, LOWER COST
One advantage in any high throughput screening campaign is the reduced number of steps in the assay, which leads to even higher throughput when used with the FLIPR system. The kits simple procedure involves the direct addition of the kit reagents to the cell plate, incubation for 20 minutes to one hour, and then dire ct transfer of the plates to the FLIPR system for data collection. (See Figure 3.) The elimination of intermediate steps reduces valuable assay time and costs. Also, due to the improved kit chemistry, clear plates may be used instead of black-walled plates to reduce disposable costs significantly.


CONVENIENT PROTOCOL
Another advantage in a high throughput screening campaign is increased convenience. Once dye-loaded with the kit reagents, cells are typically stable for several hours, maximizing assay flexibility. In addition, the FLIPR Calcium Assay Kit has been demonstrated to work equally well with both adherent and non-adherent cells. In many cases, poly-D-lysine coated plates are not required, further lowering the overall assay cost. With the FLIPR Calcium Assay Kit, non-adherent cells are less likely to lift off the plate, and they display greater responsiveness due in part to the elimination of multiple wash/centrifugation steps. Users consistently see equivalent and, in many cases, superior responses to those obtained using the conventional protocol.


ORDERING INFORMATION
For assay development on FLIPR or FLEXstation.

Calcium Assay Kit for FLIPR: Part Number: R8033
(10) reagent vials
(1) buffer bottle
Provides sufficient reagent for 100 plates (96- or 384-well)


Volume discounts given for quantities of 5, 10, and 50 unit orders.

Calcium Assay Kit for FLEXstation: Part Number: R8041
(10) reagent vials
(1) buffer bottle
Provides sufficient reagent for 10 plates (96- or 384-well)


SALES OFFICES
USA 800-635-5577
UK +44-118-944-8000
Germany +49-89-9620-2340
Japan +06-6399-8211

Check our w eb site for a current listing of our worldwide distributors.
www.moleculardevices.com


FLIPR is a registered trademark and FLEXstation is a trademark of Molecular Devices Corporation.

Contact your Molecular Devices representative for more information.


back to top


'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. FLIPR Calcium 3 Assay Kit Datasheet
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR
4. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
5. Cis-Reporting System Monitors Intracellular Calcium Mobilization
6. Cis-Reporting System Monitors Intracellular Calcium Mobilization
7. Calcium Plus Assay Kit, Superior Detection for Specialized Targets
8. Calcium Flux Assays using the LabChip 3000
9. HEK293 Calcium Flux Assay
10. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
11. Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" )
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):